
Loading, please wait...

Loading, please wait...

Neuroinflammation is a complex biological response involving various signaling molecules. Recently, researchers developed a dual-site fluorescent probe to investigate ATP NE neuroinflammation dynamics. This innovative imaging tool allows for the simultaneous visualization of Adenosine Triphosphate (ATP) and Norepinephrine (NE) without cross-coloring interference. Consequently, scientists can now observe the real-time exocytosis of these co-transmitters in living models.
ATP often acts as a signaling molecule in the central nervous system. In this neuroinflammatory model, the study shows that ATP promotes the release of NE. This finding is significant because it highlights a specific interaction that drives inflammatory progression. Moreover, identifying this pathway provides a new target for clinical intervention. Therefore, monitoring these levels could improve early diagnosis of neurodegenerative conditions.
Furthermore, the probe's high selectivity makes it a valuable asset for diagnostic research. Traditional methods often struggle to distinguish between multiple neurotransmitters simultaneously. In contrast, this dual-channel approach offers precise spatial and temporal resolution. Specifically, clinicians might use these insights to develop therapies that disrupt the ATP-mediated release of NE. Such advancements could potentially halt the cycle of chronic inflammation in the brain.
The probe utilizes two independent reactive sites with distinct emission wavelengths, allowing for the clear detection of ATP and NE in separate channels without signal overlap.
The research demonstrates that ATP acts as a co-transmitter that promotes norepinephrine (NE) exocytosis. This interaction contributes to the inflammatory environment, making it a critical focus for potential treatments.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
1. Zhou N et al. A dual-site fluorescent probe for tracing the interaction between ATP and NE in neuroinflammation. Chem Commun (Camb). 2026 Mar 30. doi: 10.1039/d6cc00862c. PMID: 41906982.
2. Wu G et al. Recent advances in fluorescent probes for ATP imaging. Talanta. 2024 Nov 1;278:126622. doi: 10.1016/j.talanta.2024.126622.
3. Yu T et al. Multifunctional Fluorescent Probe for Simultaneous Detection of ATP, Cys, Hcy, and GSH: Advancing Insights into Epilepsy and Liver Injury. Adv Sci (Weinh). 2025 Jan 30. doi: 10.1002/advs.202409543.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A dual-site fluorescent probe visualizes the interaction between ATP and NE in neuroinflammation, revealing that ATP promotes NE release as a co-transmitter...
6 months ago

As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today

A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today